Physician profile
Weidan D Zhao
NPI 1881124287
$9,762.87
in general payments reported to CMS, 2019-2025
25 companies · $3,959 in 2025
The $3,959 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.65 · 2022: $414 · 2023: $1,849 · 2024: $3,529 · 2025: $3,959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,337.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,011.69 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $2,439.28 | 2022-2025 | Rinvoq, Skyrizi, Linzess |
| Genzyme Corporation | $730.76 | 2023-2025 | |
| Qol Medical, LLC | $678.42 | 2025 | Sucraid |
| Ardelyx, INC. | $457.10 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $351.41 | 2023-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $331.52 | 2023-2025 | Dupixent |
| Pfizer INC. | $328.43 | 2019-2025 | |
| Lilly USA, LLC | $223.65 | 2024-2025 | Omvoh |
| Redhill Biopharma INC. | $200.80 | 2023-2024 | Talicia |
| Ironwood Pharmaceuticals, INC | $141.93 | 2023-2025 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $139.99 | 2024 | Zeposia |
| Glaxosmithkline, LLC. | $125.00 | 2022 | |
| Braintree Laboratories, INC. | $123.19 | 2023-2024 | Sutab, Suflave |
| Celgene Corporation | $90.00 | 2024 | Zeposia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $67.32 | 2023-2025 | Voquezna |
| Madrigal Pharmaceuticals | $61.88 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $59.22 | 2024-2025 | |
| Celltrion USA INC. | $44.70 | 2024-2025 | Vegzelma |
| Boston Scientific Corporation | $37.79 | 2022-2023 | |
| Vibrant Gastro, INC. | $36.00 | 2025 | Vibrant Starter Kit |
| Shield Therapeutics INC | $26.10 | 2025 | |
| Evoke Pharma, INC. | $23.04 | 2025 | |
| Capsovision, INC. | $20.11 | 2024 | Capsocam Plus |
| Phadia US INC. | $13.54 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weidan Zhao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.